Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Douglas Guevara

Independent Medical Examiner Miami, FL Medical Doctor

NPI 1568923043 CMS profile 7227569

1890 Red Rd Ste 108, Miami, FL 33155

Open in the dashboard

General payments

$5,356

252 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Douglas Guevara of Miami, FL is reported in the CMS Open Payments database as having received $5,356 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $819 43
2022 General $2,539 131
2021 General $1,958 75
2020 General $27 2
2019 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Guevara
  • Independent Medical Examiner median
  • Middle half of Independent Medical Examiner
  • National median

In program year 2019, general payments to Douglas Guevara were reported at $14. Among 21 Independent Medical Examiner profiles paid that year, the median was $113 and the middle half received between $25 and $528.

Show as a table
Year Douglas Guevara Independent Medical Examiner median Middle half National median
2019 $14 $113 $25–$528 $163
2020 $27 — — $114
2021 $1,958 — — $132
2022 $2,539 — — $149
2023 $819 — — $160
2024 $0 — — $164
2025 $0 — — $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $685 39 payments
  2. AstraZeneca Pharmaceuticals LP $569 17 payments
  3. Mannkind Corporation $527 23 payments
  4. Sanofi-Aventis U.S. LLC $407 18 payments
  5. Xeris Pharmaceuticals, Inc. $382 15 payments
  6. Novo Nordisk Inc $284 15 payments
  7. Esperion Therapeutics, Inc. $222 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $211 11 payments
  9. Amgen Inc. $207 11 payments
  10. AbbVie, Inc. $191 13 payments
  11. Other $1,671 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,356 252 payments
Products named General payments · program years 2019–2023
  1. AFREZZA $527 23 payments
  2. FARXIGA $344 6 payments
  3. GVOKE PFS $284 10 payments
  4. Ozempic $267 14 payments
  5. RYBELSUS $244 13 payments
  6. SOLIQUA 100/33 $238 13 payments
  7. NEXLETOL $222 7 payments
  8. JARDIANCE Diabetes $211 11 payments
  9. JARDIANCE Diabetes $191 13 payments
  10. BAQSIMI $180 9 payments
  11. Other $3,714 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Independent Medical Examiner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record